278 related articles for article (PubMed ID: 27062188)
1. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Kaufmann P; Cruz HG; Krause A; Ulč I; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2016 Aug; 82(2):369-79. PubMed ID: 27062188
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
Kaufmann P; Okubo K; Bruderer S; Mant T; Yamada T; Dingemanse J; Mukai H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):195-203. PubMed ID: 25850750
[TBL] [Abstract][Full Text] [Related]
3. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853
[TBL] [Abstract][Full Text] [Related]
4. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
Kaufmann P; Niglis S; Bruderer S; Segrestaa J; Äänismaa P; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2015 Oct; 80(4):670-7. PubMed ID: 25851691
[TBL] [Abstract][Full Text] [Related]
5. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
Bruderer S; Hurst N; Kaufmann P; Dingemanse J
Pharmacology; 2014; 94(3-4):148-56. PubMed ID: 25277144
[TBL] [Abstract][Full Text] [Related]
6. Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.
Boehler M; Bruderer S; Ulč I; Dingemanse J
Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):115-120. PubMed ID: 28639216
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study.
Baldoni D; Bruderer S; Muhsen N; Dingemanse J
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):788-98. PubMed ID: 26152132
[TBL] [Abstract][Full Text] [Related]
8. Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist.
Kaufmann P; Hurst N; Astruc B; Dingemanse J
Eur J Clin Pharmacol; 2017 Feb; 73(2):151-156. PubMed ID: 27885399
[TBL] [Abstract][Full Text] [Related]
9. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
[TBL] [Abstract][Full Text] [Related]
10. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Honorato Pérez J
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
[TBL] [Abstract][Full Text] [Related]
12. Comment on: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag".
Srinivas NR
Am J Cardiovasc Drugs; 2015 Oct; 15(5):371-2. PubMed ID: 26293236
[No Abstract] [Full Text] [Related]
13. Authors' reply to Srinivas: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag".
Kaufmann P; Dingemanse J
Am J Cardiovasc Drugs; 2015 Oct; 15(5):373-4. PubMed ID: 26293237
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys.
Ichikawa T; Yamada T; Treiber A; Gnerre C; Nonaka K
Xenobiotica; 2018 Feb; 48(2):186-196. PubMed ID: 28277164
[TBL] [Abstract][Full Text] [Related]
15. Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects.
Bruderer S; Okubo K; Mukai H; Mant T; Dingemanse J
Clin Ther; 2016 May; 38(5):1228-1236.e1. PubMed ID: 27063071
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Bruderer S; Hurst N; Remenova T; Dingemanse J
Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
[TBL] [Abstract][Full Text] [Related]
18. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.
Sidharta PN; Lindegger N; Ulč I; Dingemanse J
J Clin Pharmacol; 2014 Mar; 54(3):291-300. PubMed ID: 24122797
[TBL] [Abstract][Full Text] [Related]
20. Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
Ghosh RK; Ball S; Das A; Bandyopadhyay D; Mondal S; Saha D; Gupta A
J Clin Pharmacol; 2017 May; 57(5):547-557. PubMed ID: 27670133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
